Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy in Advanced Melanomas
- PMID: 40413009
- DOI: 10.1016/j.soc.2025.01.006
Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy in Advanced Melanomas
Abstract
Biomarkers capable of predicting adverse melanoma patient responses to immune checkpoint inhibitor (ICI) therapies are an unmet need. Clinical biomarkers are largely prognostic and current response guidelines do not reflect the complex tumor-immune cell interaction dynamics attributed to ICI therapies. Validation of enhanced predictive biomarkers is dependent upon adoption of novel spatial imaging platforms capable of quantifying immune checkpoint receptor-ligand interactions within the tumor microenvironment. Assessments of these interactions at multiple points during neoadjuvant ICI regimens would inform biomarker selection based on changes in receptor-ligand interactions that best correlate with patient survival.
Keywords: Biomarker; Immune checkpoint; Immunotherapy; Melanoma; Predictive; Quantitative; Spatial.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures The authors have nothing to disclose.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
